Skip to content

Reduction of interleukin-6 levels in patients with Friedreich's Ataxia treated with omaveloxolone.

Oct 2026 · Journal of Neurological Sciences · Vol 491, pp. 126204 · 0 citations · 43 references
Medicine

TL;DR

Omav confirmed a favorable safety and tolerability profile in adult patients with FRDA in a real-world setting after 48 weeks of treatment, and a sustained reduction in IL-6 levels supports a potential direct immunomodulatory effect of the drug, consistent with its proposed disease-modifying activity.

Abstract

Background

Friedreich's Ataxia (FRDA) is the most common inherited spinocerebellar ataxia and is caused by a homozygous GAA trinucleotide repeat expansion in the frataxin (FXN) gene, leading to reduced intramitochondrial frataxin expression with a consequent progressive neurodegeneration and multisystem involvement. Neuroinflammatory pathways may contribute to FRDA pathophysiology and IL-6 represents a biologically relevant inflammatory mediator. Recently, omaveloxolone (Omav), an activator of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, demonstrated clinically meaningful neurological benefits with a favorable safety profile.

Objectives

In this study, we report a 1-year follow-up of our real-life population treated with Omav, with a specific focus on clinical outcomes, safety, and inflammatory biomarkers.

Methods

Twenty patients with FRDA were evaluated for 48 weeks using clinical scales (mFARS, SARA, FSS, and FA-ADL) and laboratory testing. Inclusion criteria were genetically confirmed FRDA, age ≥ 16 years and mFARS <80. All patients received Omav 150 mg/day.

Results

Treatment showed a favorable safety profile, clinical stabilization and no serious adverse events with only one treatment discontinuation. IL-6 levels showed a progressive and significant reduction during follow-up. Transient hepatic enzyme elevations did not lead to treatment discontinuation.

Conclusions

Omav confirmed a favorable safety and tolerability profile in adult patients with FRDA in a real-world setting after 48 weeks of treatment. The sustained reduction in IL-6 levels further supports a potential direct immunomodulatory effect of the drug, consistent with its proposed disease-modifying activity. However, further long-term studies are warranted to better define the efficacy of Omav in FRDA.

View source

Similar papers

Review Open access Oct 2026

The Broad Clinical Heterogeneity of TRNT1-Related Autoinflammatory Syndrome: A Comprehensive Review

Mutations in the tRNA Nucleotidyl Transferase 1 (TRNT1) gene have been associated with a systemic autoinflammatory disease (SAID) that presents with a wide clinical spectrum, ranging from severe and fatal forms to milder disorders. We conducted a literature review to provide a comprehensive analysis of the clinical cha...

Simona Di Gennaro, F. Della Casa, A. Petraroli et al. · 0 citations
Oct 2026

Gain-of-Function Variants in PLAAT4 and Spinal Predominant Demyelinating Leukodystrophy.

Importance Leukoencephalopathies are clinically and etiologically heterogeneous disorders, and establishing a specific diagnosis remains challenging. Patients with unexplained spastic paraplegia and brain white matter hyperintensities (WMH) may be misdiagnosed as having multiple sclerosis, potentially exposing them to...

Yi-Heng Zeng, Bo-Li Chen, Yan Shi et al. · 0 citations
Clinical trial Open access Oct 2026

Phase 3 randomized trial of latozinemab in frontotemporal dementia due to GRN mutations

Abstract INTRODUCTION Heterozygous progranulin gene mutations causing frontotemporal dementia (FTD‐GRN) are associated with deficiency in progranulin (PGRN). Latozinemab is a human monoclonal immunoglobulin G1 (IgG1) antibody designed to elevate PGRN levels in people with heterozygous loss‐of‐function (LOF) GRN mutatio...

Adam Simmons, B. Boeve, I. Le Ber et al. · 0 citations
Open access Oct 2026

Fibromyalgia, Chronic Fatigue Syndrome, and Multiple Sclerosis are associated with lower translocator protein binding affinity genotypes

Introduction: Neuroinflammation is a known pathophysiologic mechanism in multiple sclerosis and a proposed mechanism in fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Positron Emission Tomography (PET) imaging of the translocator protein (TSPO) has been widely used to measure neuroinflamm...

C. Jones, J. Younger · 0 citations
Open access Sep 2026

Pilot clinical study of Taxifolin Aqua effect in patients with amnestic mild cognitive impairment

Taxifolin (dihydroquercetin), a potent antioxidant flavonoid, shows promise for neurodegenerative conditions. Our pilot study aimed at evaluation the efficacy and safety of Taxifolin in patients with amnestic mild cognitive impairment (aMCI) and monitored a set of blood measures. Twenty-three patients (18 female; aged...

E. Ponomareva, N. Selezneva, I. Boksha et al. · 0 citations
Review Sep 2026

Hyperinflammatory syndromes in primary mitochondrial disease: A three-center case series and focused review.

INTRODUCTION Primary mitochondrial diseases (PMtD) are increasingly recognized to involve clinically meaningful immune dysregulation in addition to bioenergetic failure. Hyperinflammatory syndromes, including secondary hemophagocytic lymphohistiocytosis (HLH) and related cytokine-mediated inflammatory states, remain un...

Daniel Brooks, Eliza M. Gordon-Lipkin, I. Elsharkawi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.